In addition, as an era of immunotherapy, this landscape of HLA polymorphisms in GBM patients may provide more understanding of immunotherapies focusing on TCR-peptide/MHC interactions such as peptide vaccines, neoantigen vaccines, and TCR-engineered T cell therapy. Here, HLA-C is linked to glioblastoma.